These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 7473162)

  • 1. Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure.
    Trippodo NC; Robl JA; Asaad MM; Bird JE; Panchal BC; Schaeffer TR; Fox M; Giancarli MR; Cheung HS
    J Pharmacol Exp Ther; 1995 Nov; 275(2):745-52. PubMed ID: 7473162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined inhibition of neutral endopeptidase and angiotensin converting enzyme in cardiomyopathic hamsters with compensated heart failure.
    Trippodo NC; Fox M; Natarajan V; Panchal BC; Dorso CR; Asaad MM
    J Pharmacol Exp Ther; 1993 Oct; 267(1):108-16. PubMed ID: 8229737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats.
    Campbell DJ; Anastasopoulos F; Duncan AM; James GM; Kladis A; Briscoe TA
    J Pharmacol Exp Ther; 1998 Nov; 287(2):567-77. PubMed ID: 9808682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension.
    Pham I; Gonzalez W; el Amrani AI; Fournié-Zaluski MC; Philippe M; Laboulandine I; Roques BP; Michel JB
    J Pharmacol Exp Ther; 1993 Jun; 265(3):1339-47. PubMed ID: 8389863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antihypertensive and natriuretic effects of CGS 30440, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase 24.11.
    Chatelain RE; Ghai RD; Trapani AJ; Odorico LM; Dardik BN; De Lombaert S; Lappe RW; Fink CA
    J Pharmacol Exp Ther; 1998 Mar; 284(3):974-82. PubMed ID: 9495857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Marked difference between angiotensin-converting enzyme and neutral endopeptidase inhibition in vivo by a dual inhibitor of both enzymes.
    Anastasopoulos F; Leung R; Kladis A; James GM; Briscoe TA; Gorski TP; Campbell DJ
    J Pharmacol Exp Ther; 1998 Mar; 284(3):799-805. PubMed ID: 9495836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction between neutral endopeptidase and angiotensin converting enzyme inhibition in rats with myocardial infarction: effects on cardiac hypertrophy and angiotensin and bradykinin peptide levels.
    Duncan AM; James GM; Anastasopoulos F; Kladis A; Briscoe TA; Campbell DJ
    J Pharmacol Exp Ther; 1999 Apr; 289(1):295-303. PubMed ID: 10087017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypotensive and natriuretic effects of RB 105, a new dual inhibitor of angiotensin converting enzyme and neutral endopeptidase in hypertensive rats.
    Gonzalez Vera W; Fournié-Zaluski MC; Pham I; Laboulandine I; Roques BP; Michel JB
    J Pharmacol Exp Ther; 1995 Jan; 272(1):343-51. PubMed ID: 7815350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase in rats with hypertension.
    French JF; Anderson BA; Downs TR; Dage RC
    J Cardiovasc Pharmacol; 1995 Jul; 26(1):107-13. PubMed ID: 7564349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repression of angiotensin II and potentiation of bradykinin contribute to the synergistic effects of dual metalloprotease inhibition in heart failure.
    Trippodo NC; Panchal BC; Fox M
    J Pharmacol Exp Ther; 1995 Feb; 272(2):619-27. PubMed ID: 7853175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of omapatrilat in low, normal, and high renin experimental hypertension.
    Trippodo NC; Robl JA; Asaad MM; Fox M; Panchal BC; Schaeffer TR
    Am J Hypertens; 1998 Mar; 11(3 Pt 1):363-72. PubMed ID: 9544878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme in rats with hypertension and diabetes mellitus.
    Tikkanen T; Tikkanen I; Rockell MD; Allen TJ; Johnston CI; Cooper ME; Burrell LM
    Hypertension; 1998 Oct; 32(4):778-85. PubMed ID: 9774379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension.
    Wallis EJ; Ramsay LE; Hettiarachchi J
    Clin Pharmacol Ther; 1998 Oct; 64(4):439-49. PubMed ID: 9797801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determinants of in vivo activity of neutral endopeptidase 3.4.24.11 and angiotensin converting enzyme inhibitors.
    Seymour AA; Asaad MM; Abboa-Offei BE; Smith PL; Rogers WL; Dorso CR
    J Pharmacol Exp Ther; 1996 Feb; 276(2):708-13. PubMed ID: 8632340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design of orally active dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme with long duration of action.
    Fournie-Zaluski MC; Coric P; Thery V; Gonzalez W; Meudal H; Turcaud S; Michel JB; Roques BP
    J Med Chem; 1996 Jun; 39(13):2594-608. PubMed ID: 8691458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of angiotensin-converting enzyme (ACE), neutral endopeptidase (NEP) and dual ACE/NEP inhibition on blood pressure and resistance arteries of deoxycorticosterone acetate-salt hypertensive rats.
    Pu Q; Touyz RM; Schiffrin EL
    J Hypertens; 2002 May; 20(5):899-907. PubMed ID: 12011651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of cardiac hypertrophy and fibrosis by S21402, a dual inhibitor of neutral endopeptidase and angiotensin converting enzyme in SHRs.
    Farina NK; Johnston CI; Burrell LM
    J Hypertens; 2000 Jun; 18(6):749-55. PubMed ID: 10872560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal recognition of neutral endopeptidase and angiotensin-converting enzyme active sites by mercaptoacyldipeptides as a means to design potent dual inhibitors.
    Coric P; Turcaud S; Meudal H; Roques BP; Fournie-Zaluski MC
    J Med Chem; 1996 Mar; 39(6):1210-9. PubMed ID: 8632427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regional hemodynamic effects of neutral endopeptidase inhibition and angiotensin (AT(1)) receptor antagonism alone or in combination in conscious spontaneously hypertensive rats.
    Gardiner SM; March JE; Kemp PA; Ballard SA; Bennett T
    J Pharmacol Exp Ther; 2006 Oct; 319(1):340-8. PubMed ID: 16825530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.